Compass-logo-RGB-outlines.png
Compass Therapeutics Announces US FDA Clearance of Investigational New Drug Application for a Phase 2 Study of CTX-009, a Bispecific Antibody That Simultaneously Targets Delta-like Ligand 4 (DLL4) and Vascular Endothelial Growth Factor A (VEGF-A)
January 20, 2022 08:30 ET | Compass Therapeutics
BOSTON, Jan. 20, 2022 (GLOBE NEWSWIRE) -- Compass Therapeutics, Inc. (Nasdaq: CMPX), a clinical-stage biopharmaceutical company developing proprietary antibody-based therapeutics to treat cancer,...
OncoMed Pharmaceuticals, Inc. Logo
OncoMed Initiates Enrollment of Phase 1b Clinical Trial of Anti-DLL4/VEGF Bispecific Antibody as Second-line Treatment for Metastatic Colorectal Cancer Patients
January 04, 2017 08:30 ET | OncoMed Pharmaceuticals, Inc.
REDWOOD CITY, Calif., Jan. 04, 2017 (GLOBE NEWSWIRE) -- OncoMed Pharmaceuticals, Inc. (NASDAQ:OMED), a clinical-stage company focused on discovering and developing novel anti-cancer stem cell and...
Lymfactin(TM) Found to Significantly Increase Growth of Lymphatic Vessels in Animal Study; Results Seen as "Pathway to a Breakthrough" for Breast Cancer Patients Who Would Benefit From Lymph Node Transfers for Lymphedema
September 23, 2011 05:00 ET | Laurantis Pharma
MALMO, SWEDEN--(Marketwire - Sep 23, 2011) - Laurantis Pharma, a privately held biotechnology company based in Finland, today announced that Lymfactin™, adenoviral VEGF-C growth factor...